The relentless mutational march of the SARS-CoV-2 virus has birthed a highly altered new strain. The BA.3.2 Omicron subvariant, newly nicknamed “Cicada” by researchers, has now been detected across 29 US states and Puerto Rico. But despite carrying an estimated 70 to 75 new spike protein mutations, infectious disease experts are urging the public to remain calm.
Current data shows no indication that the Cicada strain causes increased severity, hospitalizations, or deaths compared to other recent variants. Dr. Jake Scott of Stanford University and Marc Veldhoen from the University of Lisbon have advised people to treat the variant with serious attention, not alarm. The current vaccine formulations appear to be doing exactly what they were designed to do, according to a detailed report published on Saturday. They prevent severe disease.
The variant’s nickname comes from its genetic history. It descended from the BA.3 Omicron lineage. That specific lineage had not actively circulated globally since early 2022. Researchers believe this sudden re-emergence means the virus mutated completely undetected for a prolonged period. This likely occurred as a sudden genetic leap within a chronically infected or immunocompromised host.
Right now, the World Health Organization classifies BA.3.2 strictly as a variant under monitoring. They have declined to upgrade it to a higher-risk designation.
There has been some concern regarding younger demographics. BA.3.2 is currently overrepresented in pediatric samples logged in the GISAID tracking database. However, officials caution against jumping to conclusions. There is no confirmed evidence that the strain preferentially targets children or makes them sicker.
Yes, it's accurate. The BA.3.2 "Cicada" variant (an Omicron offshoot) has been detected in at least 25 U.S. states per CDC surveillance data from February 2026, including via wastewater sampling. It's spreading slowly globally but isn't driving major case surges or severe…
— Grok (@grok) April 4, 2026
The Centers for Disease Control and Prevention is aggressively tracking the spread. They are relying heavily on wastewater surveillance. This same wastewater tracking first picked up the strain in the US back in mid-2025 from a traveler arriving from the Netherlands. This ongoing monitoring comes at a critical time for public health as many major clinical sequencing programs continue to scale back their operations. The variant has already been reported in at least 23 countries globally.
How the Cicada Strain Complicates the May 2026 Vaccine Formulation
The sudden emergence of a strain with 75 mutations presents a massive logistical hurdle for global medical authorities. Because laboratory data shows BA.3.2 can partially evade antibodies generated by current vaccines, the WHO’s Technical Advisory Group on COVID-19 Vaccine Composition is actively scrutinizing the virus. Their findings over the next few weeks are critical.
The immune-escape capabilities of the Cicada variant will heavily dictate the policy deliberations scheduled for May 2026. That is when officials must finalize exactly how next year’s seasonal vaccines are formulated. If Cicada continues to outcompete older strains, pharmaceutical manufacturers will need to rapidly shift their production lines to match this aggressive new genetic profile.